BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 228106)

  • 1. Suppression of the immune response in tumor-bearing mice. II. Characterization of adherent suppressor cells.
    Bluestone JA; Lopez C
    J Natl Cancer Inst; 1979 Nov; 63(5):1221-7. PubMed ID: 228106
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Suppression of the immune response in tumor-bearing mice. I. Response to virus-producing tumor cells and non-virus-producing tumor cells.
    Bluestone JA; Lopez C
    J Natl Cancer Inst; 1979 Nov; 63(5):1215-20. PubMed ID: 228105
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Significance of suppressor macrophages for immunosurveillance of tumor-bearing mice.
    Fujii T; Igarashi T; Kishimoto S
    J Natl Cancer Inst; 1987 Mar; 78(3):509-17. PubMed ID: 2950265
    [TBL] [Abstract][Full Text] [Related]  

  • 4. T cell-mediated immunity to oncornavirus-induced tumors. III. Specific and nonspecific suppression in tumor-bearing mice.
    Plater C; Debré P; Leclerc JC
    Eur J Immunol; 1981 Jan; 11(1):39-44. PubMed ID: 6452278
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of gp70-specific suppressor T-cells in mice inoculated with virus-producing tumor cells.
    Bluestone JA; Lopez C
    J Natl Cancer Inst; 1982 Oct; 69(4):953-9. PubMed ID: 6214655
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Suppressor cell activity in tumor-bearing mice. I. Dualistic inhibition by suppressor T lymphocytes and macrophages.
    Elgert KD; Farrar WL
    J Immunol; 1978 Apr; 120(4):1345-53. PubMed ID: 305939
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Defects in cell-mediated and humoral immunity in tumor-bearing mice. Evidence and characterization of suppressor cells ].
    Siegl E; Günther J; Schulze HA; Brock J
    Allerg Immunol (Leipz); 1981; 27(3):153-61. PubMed ID: 6214936
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor cell-triggered macrophage-mediated suppression of the T-cell cytotoxic response to tumor-associated antigens. I. Characterization of the cell components for induction of suppression.
    Ting CC; Rodrigues D
    J Natl Cancer Inst; 1982 Oct; 69(4):867-72. PubMed ID: 6214653
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of T-cells in the mechanism of reactivity of the microplate leukocyte adherence inhibition assay.
    Raina S; Russo AJ; Jenkins D; Goldrosen MH
    Cancer Res; 1981 Oct; 41(10):3950-5. PubMed ID: 6456811
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor-induced regulation of suppressor macrophage nitric oxide and TNF-alpha production. Role of tumor-derived IL-10, TGF-beta, and prostaglandin E2.
    Alleva DG; Burger CJ; Elgert KD
    J Immunol; 1994 Aug; 153(4):1674-86. PubMed ID: 8046239
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased susceptibility to tumor cell immunosuppressive effect in tumor-bearing mice.
    Ting CC; Rodrigues D
    J Natl Cancer Inst; 1980 Jul; 65(1):205-9. PubMed ID: 6967124
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor-specific suppressor T-cells which inhibit the in vitro generation of cytolytic T-cells from immune and early tumor-bearing host spleens.
    Bear HD
    Cancer Res; 1986 Apr; 46(4 Pt 1):1805-12. PubMed ID: 2936451
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective immunomodulation by the antineoplastic agent mitoxantrone. II. Nonspecific adherent suppressor cells derived from mitoxantrone-treated mice.
    Fidler JM; DeJoy SQ; Smith FR; Gibbons JJ
    J Immunol; 1986 Apr; 136(8):2747-54. PubMed ID: 2937837
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Matching of chemotherapy to mouse strain and lymphoid tumor type to prevent tumor-induced suppression of specific T- and B-cell functions.
    Faanes RB; Merluzzi VJ; Williams N; Tarnowski GS; Ralph P
    Cancer Res; 1979 Nov; 39(11):4564-74. PubMed ID: 315269
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modification of host antitumor defense mechanisms in mice by progressively growing tumor.
    Maccubbin DL; Mace KF; Ehrke MJ; Mihich E
    Cancer Res; 1989 Aug; 49(15):4216-24. PubMed ID: 2525950
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Graft-vs-host reactions (GVHR) across minor murine histocompatibility barriers. II. Development of natural suppressor cell activity.
    Maier T; Holda JH; Claman HN
    J Immunol; 1985 Sep; 135(3):1644-51. PubMed ID: 3160774
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy of a chemically-induced sarcoma in rats: characterization of the effector T cell subset and nature of suppression.
    Fernandez-Cruz E; Gilman SC; Feldman JD
    J Immunol; 1982 Mar; 128(3):1112-7. PubMed ID: 6460058
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stimulation of mouse migration inhibitory factor (MIF) production form MSV-immune lymphocytes by soluble tumor-associated antigen: requirement for histocompatible macrophages.
    Landolfo S; Herberman RB; Holden HT
    J Immunol; 1977 Apr; 118(4):1244-8. PubMed ID: 191532
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Generation of cytotoxic T lymphocytes during coxsackievirus tb-3 infection. II. Characterization of effector cells and demonstration cytotoxicity against viral-infected myofibers1.
    Wong CY; Woodruff JJ; Woodruff JF
    J Immunol; 1977 Apr; 118(4):1165-9. PubMed ID: 300400
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Down-regulation of cytotoxic T lymphocyte development by a minor stimulating locus-induced suppressor cascade that involves Lyt-1+ suppressor T cells, IA- macrophages, and their factors.
    Chow KP; Battisto JR
    J Immunol; 1988 Feb; 140(4):1005-13. PubMed ID: 2963857
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.